Companies · Biotechnology

NanoVibronix, Inc.

ELMSFORD · Biotechnology

Diligence memoA one-page analyst read on NanoVibronix, Inc. — recommendation, valuation, rhythm, risks.
$31.9M
Total raised · real
15
Rounds
54.2×
Latest step-up
Top 26%
Sector rank · raised
Series A
Latest stage · inferred · Wed Aug 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

NanoVibronix, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.40× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.8 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

NanoVibronix, Inc. is one of 4293 Biotechnology companies tracked from ELMSFORD. By capital raised it ranks in the upper tier (ahead of 75% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2023-08-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2003-11-04 Raised $909K (real) Modeled valuation $50M (est)Pre-Seed2003Pre-Seed · 2004-11-01 Raised $218K (real) Modeled valuation $12M (est)Pre-Seed2004Seed · 2005-02-06 Raised $2.5M (real) Modeled valuation $111M (est)Seed2005Seed · 2009-03-01 Raised $1.4M (real) Modeled valuation $60M (est)Seed2009Seed · 2011-11-21 Raised $1.0M (real) Modeled valuation $44M (est)Seed2011Seed · 2013-02-05 Raised $100K (real) Modeled valuation $4.4M (est)Seed2013Seed · 2013-02-05 Raised $1.5M (real) Modeled valuation $67M (est)Seed2013Seed · 2015-01-29 Raised $3.1M (real) Modeled valuation $140M (est)Seed2015Seed · 2015-04-07 Raised $257K (real) Modeled valuation $11M (est)Seed2015Seed · 2017-03-01 Raised $250K (real) Modeled valuation $11M (est)Seed2017Seed · 2017-03-23 Raised $100K (real) Modeled valuation $4.4M (est)Seed2017Seed · 2020-06-22 Raised $450K (real) Modeled valuation $20M (est)Seed2020Series A · 2020-12-02 Raised $6.6M (real) Modeled valuation $194M (est)Series A2020Series A · 2021-01-22 Raised $1.3M (real) Modeled valuation $35M (est)Series A2021Series A · 2022-06-14 Raised $250K (real) Modeled valuation $3.5M (est)Series A2022Series A · 2023-08-30 Raised $14M (real) Modeled valuation $107M (est)Series A2023Cumulative $33M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$909K · 2003
Pre-Seed extension$218K · 2004
Seed$2.5M · 2005
Seed extension$1.4M · 2009
Seed extension$1.0M · 2011
Seed extension$100K · 2013
Seed extension$1.5M · 2013
Seed extension$3.1M · 2015
Seed extension$257K · 2015
Seed extension$250K · 2017
Seed extension$100K · 2017
Seed extension$450K · 2020
Series A$6.6M · 2020
Series A extension$1.3M · 2021
Series A extension$250K · 2022
Series A extension$13.5M · 2023

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$106.6M
Base estimate est.
$14.8M
Conservative case
$279.7M
Upside case
$61.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $50.2M · 2003-11-042003Pre-Seed · modeled $12.1M · 2004-11-01Seed · modeled $111.0M · 2005-02-06Seed · modeled $60.2M · 2009-03-01Seed · modeled $44.4M · 2011-11-21Seed · modeled $4.4M · 2013-02-05Seed · modeled $66.6M · 2013-02-05Seed · modeled $139.9M · 2015-01-29Seed · modeled $11.4M · 2015-04-07Seed · modeled $11.1M · 2017-03-01Seed · modeled $4.4M · 2017-03-23Seed · modeled $20.0M · 2020-06-22Series A · modeled $193.7M · 2020-12-02Series A · modeled $34.6M · 2021-01-22Series A · modeled $3.5M · 2022-06-14Series A · modeled $106.6M · 2023-08-302023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
2.8 yr
Elapsed time used
2.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$1.6M/yr
Capital velocity
22.7 yr
On record since
2003
First round
16
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.4× above median
This company$31.9M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.5× above median
This company$13.5M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.7× above median
This company$106.6M
Sector median$64.2M

Raised more than 75% of sector peers (real $). Modeled value above 60% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #41 of 303.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)NanoVibronix, Inc. (this company) Raised $31.9M · modeled $106.6M (est)NanoVibronix, Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
NanoVibronix, Inc. this companySeries A$31.9M$106.6M2.40×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$909K2003-11-04$5.0M$50.2M85%
Pre-Seed$218K2004-11-01$1.2M$12.1M85%
Seed$2.5M2005-02-06$12.5M$111.0M85%
Seed$1.4M2009-03-01$6.8M$60.2M85%
Seed$1.0M2011-11-21$5.0M$44.4M85%
Seed$100K2013-02-05$500K$4.4M85%
Seed$1.5M2013-02-05$7.5M$66.6M85%
Seed$3.1M2015-01-29$15.8M$139.9M85%
Seed$257K2015-04-07$1.3M$11.4M85%
Seed$250K2017-03-01$1.3M$11.1M90%
Seed$100K2017-03-23$500K$4.4M90%
Seed$450K2020-06-22$2.3M$20.0M90%
Series A$6.6M2020-12-02$29.8M$193.7M90%
Series A$1.3M2021-01-22$5.7M$34.6M90%
Series A$250K2022-06-14$1.1M$3.5M90%
Series A$13.5M2023-08-30$61.6M$106.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$909K2003-11-04
    • First recorded raise — entered as Pre-Seed.
    • 27 investors on this round.
  2. Pre-Seed$218K2004-11-01
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 4.2× smaller than the prior — bridge or down round.
    • 11 investors on this round.
  3. Seed$2.5M2005-02-06
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 11.5× larger than the prior — scaling up.
    • 15 investors on this round.
  4. Seed$1.4M2009-03-01
    • Raised again after 49 mo — slower than the ~14 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 28 investors on this round.
  5. Seed$1.0M2011-11-21
    • Raised again after 33 mo — slower than the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • Switched to Rule 06 (was Rule 506(b)).
    • 17 investors on this round.
  6. Seed$100K2013-02-05
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 10.0× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  7. Seed$1.5M2013-02-05
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 15.0× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 2 investors on this round.
  8. Seed$3.1M2015-01-29
    • Raised again after 24 mo — slower than the ~14 mo sector norm.
    • Round 2.1× larger than the prior — scaling up.
    • 7 investors on this round.
  9. Seed$257K2015-04-07
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 12.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  10. Seed$250K2017-03-01
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 3 investors on this round.
  11. Seed$100K2017-03-23
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  12. Seed$450K2020-06-22
    • Raised again after 39 mo — slower than the ~14 mo sector norm.
    • Round 4.5× larger than the prior — scaling up.
    • 1 investor on this round.
  13. Series A$6.6M2020-12-02
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 14.6× larger than the prior — scaling up.
    • 13 investors on this round.
  14. Series A$1.3M2021-01-22
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 5.2× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  15. Series A$250K2022-06-14
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 5.0× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  16. Series A$13.5M2023-08-30
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 54.2× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2024 ~Q4
Modeled next raise · ~16mo cadence
$40.6M
Modeled next size est.range $26.4M$65.0M
54.2×
Last step-up
$1.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Brian Murphy14 other2017-03
STEPHEN BROWN7 other2003-11
James Cardwell3 other2020-06
Ira Greenstein2 other2003-11
Harold Jacob1 other2003-11
Paul Packer1 other2011-11
Thomas Mika1 other2017-03
Thomas R Mika1 other2015-04
William Stern1 other2003-11
Aurora R. Cassirer2022-06
Christopher Fashek2017-03
Jona Zumeris2003-11
Maria R. Schroeder2022-06
Martin Goldstein2017-03
Martin R Goldstein2015-04
Michael Ferguson2015-04
Mika R. Thomas2022-06
Sim Fass2011-11
Registry & provenance

NanoVibronix, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1326706
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
NeuBase Therapeutics, Inc.BiotechnologySeries A$17.1M$42.8Mnetwork1 shared operator · same sector · same stage
Cellics Therapeutics, Inc.BiotechnologySeries A$33.0M$116.6Msame sector · same stage
Biotime IncBiotechnologySeries A$36.3M$126.5Msame sector · same stage
AsclepiX Therapeutics, Inc.BiotechnologySeries A$28.0M$83.5Msame sector · same stage
Theraclone Sciences, Inc.BiotechnologySeries A$36.7M$111.3Msame sector · same stage
Serimmune Inc.BiotechnologySeries A$27.5M$83.5Msame sector · same stage
Biolex Therapeutics, Inc.BiotechnologySeries A$26.9M$85.5Msame sector · same stage
MetaStat, Inc.BiotechnologySeries A$39.2M$122.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Nanologix IncBiotechnologySeries A$97.1M89%
NanoMolecularDX, LLCBiotechnologySeed$91.3M88%
NanoMosaic Inc.BiotechnologySeries C$16.0M88%
NanoTomer, Inc.BiotechnologyPre-Seed$52.4M88%
Integrated Nano-Technologies, Inc.BiotechnologySeries A$227.8M87%
nanoMAG, LLCBiotechnologySeed$126.9M87%
NanoCellect Biomedical, Inc.BiotechnologySeries B$322.9M87%
NanoView Biosciences, Inc.BiotechnologySeries A$41.3M87%
Frequently asked
How much funding has NanoVibronix, Inc. raised?
NanoVibronix, Inc. has raised approximately $31.9M in disclosed capital across 15 recorded financing rounds, aggregated from public filings.
What is NanoVibronix, Inc.'s estimated valuation?
Provath's modeled valuation for NanoVibronix, Inc. is approximately $106.6M (modeled range $14.8M–$279.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is NanoVibronix, Inc. at?
NanoVibronix, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Aug 30.
What does NanoVibronix, Inc. do and where is it based?
NanoVibronix, Inc. operates in the Biotechnology sector, based in ELMSFORD.
Explore related

See where NanoVibronix, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at NanoVibronix, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.